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ABSTRACT 
Background and Objectives 
The risk of developing ovarian hyperstimulation syndrome post-induction of 
ovulation in patients undergoing in-vitro fertilisation has been greatly reduced by 
the introduction of gonadotropin-releasing hormone agonists for ovulation 
induction. The pregnancy outcomes have not been fully evaluated and specifically 
not when fresh embryo transfer takes place on day three or day five of the 
medicated cycle as opposed to frozen embryo transfer in a fresh non-medicated 
cycle.  
The objectives of this study were: 
1. To evaluate the incidence of moderate to severe ovarian hyper-stimulation 
in patients undergoing gonadotropin-releasing hormone agonist induced ovulation  
2. To evaluate the pregnancy rates achieved when gonadotropin-releasing 
hormone agonist induced ovulation takes place and embryos are transferred fresh 
as opposed to frozen 
3.  To assess parameters such as stimulation drug used, pre-trigger oestrogen 
values and pre-treatment anti-Mullerian hormone and evaluate them with respect 
to pregnancy outcomes in order to isolate the best candidates for gonadotropin 
releasing hormone agonist induced ovulation induction 
 Methods 
This was a descriptive study done at the Vitalab Centre for Assisted Conception. 
All patients undergoing in-vitro fertilisation and placed on the Cetrotide® - 
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[cetrorelix acetate (gonadotropin-releasing hormone antagonist)] between the 
months of April 2010 through to April 2011 were used for the study. These patients 
had undergone ovulation induction with Lucrin® - [Leuprorelin acetate 
(gonadotropin releasing hormone agonist)]. Patients younger than 18 and older 
than 35 were excluded along with those defined as poor responders to in-vitro 
fertilisation.  
Results 
Forty eight of the 59 patients had more than 18 leading follicles at stimulation.  The 
mean leading follicle size was 16.8mm.  The interquartile range for pre-trigger 
estradiol was 12575 – 23672pmol/L with a mean of 18337pmol/L.  Seven of the 59 
subjects were coasted and only one patient developed moderate ovarian 
hyperstimulation syndrome.  Only 2 patients had zero oocytes collected while four 
patients did not have embryo transfers. The biochemical pregnancy rate was 39% 
at 14 day post embryo transfer and the clinical pregnancy rate was 34% at the 
seven week ultrasound.   
Conclusion 
Gonadotropin-releasing hormone agonist ovulation trigger almost entirely 
eliminates the risk of ovarian hyperstimulation syndrome and when fresh embryo 
transfer takes place it results in biochemical and clinical pregnancy rates which are 
acceptable. The use of intensive luteal phase support needs further work to 
establish whether the pregnancy rate would be so high without it.    
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1. Introduction 
For a couple struggling to conceive, assisted reproductive techniques (ART) 
including in-vitro fertilisation (IVF) offers them some hope of one day joining the 
ranks of parenthood. A study by Domar et al done across four European countries 
showed that women undergoing fertility treatment felt more hopeful and closer to 
their husbands than those women struggling to conceive but not going for any 
treatment.1 As much as IVF offers these couples the chance to conceive, it comes 
with a tremendous burden on couples who have to undergo the treatment. IVF is 
an expensive procedure for which many couples save money for months or even 
years. The average cost of an uncomplicated IVF cycle in Johannesburg, South 
Africa is roughly R35 0002. IVF also confers a significant burden on one’s family, 
and social life, work performance and emotional wellbeing. A recent study by 
Pinto-Gouveia et al looked at one hundred women with known infertility compared 
with one hundred couples that did not have fertility problems. The study found that 
the couples struggling with infertility exhibited higher scores on depression and 
lower scores on acceptance and self-compassion, as compared to the control 
group.3 
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2. Literature review 
2.1. History of IVF 
The first child born from IVF conception was Louise Brown, born in Oldham, 
England in July 1978 after work done by Robert Edwards and Patrick Steptoe.4 
An Australian clinic, Monash IVF, achieved the first pregnancy in a woman without 
ovaries in 1983 after using donor eggs and a special hormonal formula to support 
the first ten weeks of pregnancy.5  
The first pregnancy following intracytoplasmic sperm injection (ICSI) took place in 
1992.6 Since then reproductive medicine has developed to an extent that we now 
have the ability to screen for genetic defects in an embryo before it is transferred 
to the uterus, thus eliminating certain genetic diseases in a child or population7 . 
2.2. Normal ovulation and fertilisation8 
To understand the role of medicated fertility cycles, it is important to appreciate 
normal ovarian function. This shall be explained briefly in the following description. 
Ovulation typically takes place under tight control of the hypothalamic-pituitary-
ovarian axis. Pulsatile productions of gonadotropin-releasing hormones (GnRH) by 
the hypothalamus stimulate the pituitary to produce gonadotropins namely: follicle 
stimulating hormone (FSH) and luteinizing hormone (LH). Gonadotropins in turn 
stimulate the ovaries to produce progesterone and oestrogen which act with a 
negative feedback on the pituitary causing it to produce a smaller amount of 
gonadotropins. The first day of the menstruation is known as day (D) 1. There is a 
significant rise in the FSH levels during the first four days of the cycle stimulating 
the development of a primary follicle in the ovary. The primary follicles undergo 
specific changes until one of them becomes the dominant follicle. Only one 
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primary follicle usually becomes the dominant follicle and this selection depends 
on the number of FSH and oestrogen receptors produced on the dominant follicle.  
The primary follicles and then later the dominant follicle produce oestrogen which; 
stimulates the development of a glandular proliferative endometrium, turns the 
cervical mucus into a medium receptive to sperm and acts with positive and 
negative feedback on the pituitary to either increase or decrease the production of 
FSH and LH. The oestrogen level rises and when it reaches approximately 
300pg/ml at roughly D12-D13 of the cycle, it causes an LH surge which in turn 
impacts on the dominant follicle, now known as the pre-ovulatory follicle, for 
ovulation. LH promotes luteinisation of the granulosa cells in the dominant follicle 
resulting in the production of progesterone. Ovulation occurs roughly 10-12 hours 
after the LH surge. The progesterone level in the follicle continues to rise causing 
a negative feedback and a termination of the LH surge. Progesterone then causes 
an increase in permeability to water, of the follicle wall, rapidly increasing the 
follicular fluid volume. Changes in the collagen of the follicular wall make it thinner 
and cause it to stretch. In the presence of prostaglandins which cause contractions 
of the smooth muscle cells of the ovary, ovulation takes place. Post ovulation, the 
granulosa cells are luteinised and organise to form the corpus luteum which 
begins secreting progesterone peaking roughly on D9 post ovulation. The corpus 
luteum rapidly declines after nine to eleven days post ovulation unless ovulation 
results in a pregnancy during which human chorionic gonadotropin (hCG) will be 
secreted and the corpus luteum will survive.8 
2.3. In-vitro fertilisation 
In–vitro fertilisation is the process where an egg is fertilised by a sperm outside of 
the body. IVF is an assisted reproductive technique during which the woman 
15 
 
undergoes a heavily medicated and manipulated cycle stimulating the ovaries to 
produce multiple dominant follicles with the aid of drugs such as synthetic FSH 
known as controlled ovarian hyper-stimulation (COH). There are two protocols 
currently described for IVF namely the “long protocol” and the “short protocol”.  
During the long protocol, the pituitary-ovarian axis is down-regulated by the 
administration of a gonadotropin-releasing hormone (GnRH) agonist. The ovaries 
are then hyper-stimulated by the administration of injectable gonadotropins - FSH 
analogues. The administration of these FSH analogues usually begins 10-14 days 
after the initiation of the down regulation of the pituitary-ovarian axis. Down-
regulation of the pituitary-ovarian axis is necessary to assist the physician in 
preventing premature luteinisation - it prevents the natural process of ovulation 
taking place. Since high doses of gonadotropins are administrated to hyper-
stimulate the ovaries, the physician requires full control of the timing of ovulation, 
as it must coincide with the leading follicles being of the correct size and number.  
 The short protocol omits the down regulation of the pituitary-ovarian axis and FSH 
analogues are used to encourage follicular development during a natural cycle. In 
a short protocol ovulation is suppressed by the administration of a GnRH 
antagonist towards the end of the follicular phase of the cycle. During both the 
long and short protocols, the response of the ovaries is monitored by the use of 
transvaginal ultrasound and oestrogen levels. Ultrasound monitoring indicates 
when there are 2 or more leading follicles measuring more than 17mm each. Once 
this is seen, ovulation induction can take place.  
Ovulation induction is defined as the stimulation of final oocyte maturation and 
ovulation by means of the administration of either synthetic human-chorionic 
gonadotropin (hCG) or more recently a gonadotropin-releasing hormone agonist.9 
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Ovulation induction is akin to a synthetic LH surge and can be achieved by the 
administration of a low dose of hCG resulting in final oocyte maturation and 
ovulation roughly 36-48 hours later.10 Ovulation induction may also be achieved by 
the administration of a GnRH-agonist resulting in a more natural LH surge.11 Once 
ovulation induction has taken place, transvaginal oocyte retrieval can take place. 
Under ultrasound guidance, one end of a hollow needle is inserted transvaginally 
into the ovary. The other end is attached to a suction device and gentle suction is 
applied to aspirate the follicular fluid and oocytes. The procedure is repeated for 
both ovaries and takes place under conscious sedation, general anaesthesia or 
regional anaesthesia12, 13. Once the oocytes have been collected, oocyte and 
sperm preparation can take place. The oocytes are identified and stripped of 
surrounding cells to be prepared for fertilisation. Semen is prepared from the 
ejaculate by removing inactive cells and seminal fluid in a process known as 
“sperm washing”. Sperm may be washed by means of density gradient 
centrifugation or by the “direct swim-up” method.14 The sperm and oocytes are 
then incubated in a culture medium at a ratio of about 75000 sperm to 1 oocyte.15 
Typically embryos are cultured until they reach a 6-8 cell stage roughly day three 
post fertilisation although they may be grown in an extended medium till day 5. 
Embryo transfer takes place either on D3 or D5, or can be done using frozen-
thawed embryos and is done as a conscious procedure under ultrasound 
guidance. The embryos judged to be the best based on the embryologist’s opinion 
are loaded into a plastic catheter which is passed through the cervix and are 
expelled from the catheter high into the uterus by the aid of a syringe. The number 
of embryos transferred will depend on the amount available, the choice of the 
physician and patient, and the circumstances of the patient.   
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2.4. Ovarian hyper-stimulation syndrome (OHSS) 
With the process described above, one can imagine the added stress on a couple 
and health care provider when an IVF cycle needs to be cancelled. There are 
many reasons for having to cancel an IVF cycle with ovarian hyper-stimulation 
syndrome (OHSS) being one of them. In a study by Aljawoan et al looking  at a 
group of patients undergoing IVF/ICSI with more than 20 follicles at the time of 
ovulation induction, 10.4% of those that had three leading follicles greater than 
15mm and a serum estradiol level greater than 1635pg/ml (±6000pmol/L) 
developed moderate to severe  OHSS.16  
OHSS is almost exclusively iatrogenic and is caused by the administration of 
synthetic hCG used to trigger final oocyte maturation prior to oocyte collection.17 
The incidence of OHSS has been estimated to occur in 1% to 10% of cases of IVF 
and occurs as a serious life threatening condition in 0.1% to 2% of assisted 
reproductive cycles.18 OHSS is a systemic disease resulting from vasoactive 
products released by hyper-stimulated ovaries. OHSS is characterised by 
increased capillary permeability leading to leakage of fluid from the vascular 
compartment leading to third space fluid accumulation and intravascular 
dehydration.19 OHSS results in a massive fluid shift resulting in an accumulation of 
up to 17 litres of fluid in the peritoneal cavity. This fluid collection results in organ 
dysfunction, respiratory and circulatory failure.20  
According to the latest classification by Golan, OHSS is divided into mild, 
moderate, severe and critical OHSS.21 
 Mild OHSS: characterised by abdominal swelling, mild abdominal pain and 
ovarian size less than 8cm. 
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 Moderate OHSS: characterised by moderate abdominal pain, nausea and 
vomiting, ultrasound evidence of ascites and ovarian size between 8 and 
12cm.  
 Severe OHSS: includes clinical ascites, oliguria, haematocrit above 45%, 
hypoproteinaemia and ovarian size greater than 12cm.  
 Patients with critical OHSS need intensive care admission. These patients 
present with tense ascites, pleural effusions, haematocrit above 55%, white 
cell counts above 25000cells/ml, oliguria or anuria, thromboembolism 
related to OHSS and acute respiratory distress syndrome (ARDS). 
 Moderate to severe OHSS has been estimated to occur in 0.2% to 2% of ovarian 
stimulation cycles.22 OHSS can be further divided into early onset and late onset 
OHSS. Early onset OHSS occurs in the luteal phase and is directly linked to the 
administration of exogenous hCG. Late onset OHSS occurs when the treatment 
results in a pregnancy and is as a result of endogenous hCG following 
conception.23 
As with all medical conditions, prevention is better than cure and thus profiling 
high- risk patients that are at risk of developing OHSS is a crucial step in fertility 
treatment. Risk factors for OHSS have been identified and categorised as primary 
and secondary risk factors.  
Primary risk factors include:  
 young age (less than 33 years old), 
 polycystic ovarian syndrome (PCOS) 
 previous OHSS.24  
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Secondary risk factors are indicated by ovarian response to the stimulation and 
are assessed during the stimulation phase and include:  
 high number of medium and large sized follicles generally greater than 20 
follicles all less than 14mm 
 high or rapidly rising E2 levels above 3000pg/ml  
 number of oocytes retrieved.25 
2.5. Prevention of OHSS 
Once primary or secondary risk factors have been identified, numerous options 
are available to the clinician to prevent OHSS from developing. A recent 
publication suggests that individualized controlled ovarian stimulation is the way to 
prevent OHSS. Some measures available include cycle cancelation, coasting; the 
use of a GnRH-agonist in place of recombinant hCG for final oocyte maturation, 
individualisation of the hCG trigger and cryopreserving all embryos for subsequent 
transfer in an un-stimulated cycle.26 Cycle cancellation can be both financially and 
emotionally crippling to a patient and is reserved as a last resort in cases where 
OHSS may be severe or critical. Coasting is used to decrease the level of serum 
estradiol by withholding the exogenous gonadotropins while still administering the 
GnRH-antagonist. This method reduces the number of granulosa cells on the 
dominant follicles and in turn reduces the amount of circulating estradiol. 
Withholding of exogenous FSH causes accelerated apoptosis of granulosa cells 
and atresia of the smaller follicles and thereby reduces the number of follicles.27 
Individualisation of the hCG trigger still poses a threat of both early and late onset 
OHSS.  
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Previously ovulation induction took place with the administration of synthetic hCG. 
More recently, to prevent OHSS, newer agents such as gonadotropin-releasing 
hormone(GnRH) agonists have been used to induce ovulation.28 In order to use a 
GnRH-agonist to induce ovulation, a GnRH-antagonist must be used to prevent 
the premature LH surge and uncontrolled ovulation. Administration of a GnRH-
agonist induces an LH surge from the pituitary similar to the spontaneous mid-
cycle LH surge. Because GnRH-agonists have been used to desensitize the 
pituitary during the standard IVF cycles, it has not been widely used as a means to 
trigger final oocyte maturation. Since the introduction of GnRH-antagonists to 
prevent the premature LH surge, the use GnRH-agonists for final oocyte 
maturation and ovulation induction is now possible.29 A 2011 Cochrane review of 
the use of a GnRH-antagonist to prevent premature LH surge compared with 
GnRH-agonist showed a reduction in the incidence of moderate to severe OHSS 
while live birth rate and on-going pregnancy rates were comparable with a 95% 
confidence.30 Manzanares et al showed that triggering ovulation with a GnRH-
agonist followed by embryo cryopreservation allows patients with polycystic 
ovaries to complete COH in vitro fertilisation (IVF) without any cycle cancellation, 
coasting or OHSS. Manzanares also found the pregnancy outcomes to be 
comparable to non-GnRH-agonist trigger cycles such as recombinant hCG.31 In 
the abovementioned study the clinical pregnancy rate was 33%.28 This study 
looked at a protocol in which embryos were frozen and then transferred in a fresh 
non-medicated cycle. Originally, the thinking was that embryos derived from a 
cycle in which a GnRH-agonist was used for ovulation induction, must be frozen 
and transferred a month later in a natural non-medicated cycle. The reasoning 
behind this was that the very short endogenous LH surge caused a subsequent 
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defective corpus luteum and in turn impacted on the implantation of the embryo 
and resulted in lower pregnancy rates.32 
The reason for the comparable pregnancy rates in the study by Manzanares was 
because the embryos were frozen and transferred a month later in a non-
medicated cycle.  
In a systematic review and meta-analysis, Griesinger et al looked at the use of a 
GnRH-agonist to trigger final oocyte maturation in a GnRH-antagonist, ovarian 
stimulation protocol. In these studies the embryos were not cryopreserved and 
were transferred in a medicated cycle. Twenty three publications were identified of 
which three fulfilled the inclusion criteria for the meta-analysis. The likelihood of 
achieving a clinical pregnancy when embryos were not frozen was found to be 
considerably reduced with an odds ratio of 0.22, (95% CI = 0.05-0.85, p=0.03).33  
A 2010 Cochrane review by Youssef et al looked at 11 randomised control trials 
(RCT)s of which eight studies assessed fresh autologous cycles. In fresh, non-
donor cycles, GnRH-agonist was less effective than hCG in terms of the live birth 
rate per randomised woman (OR 0.44, 95% CI 0.29 - 0.68; 4 RCTs) and on-going 
pregnancy rate per randomised woman (OR 0.45, 95% CI 0.31 - 0.65; 8 RCTs). 
This study proposed that for a group of patients with a 30% chance of live birth 
rate using hCG, GnRH would reduce the chances to between 12% and 20%. 
Moderate to severe OHSS incidence was significantly lower in the GnRH-agonist 
group compared to the hCG group (OR 0.10, 95% CI 0.01 - 0.82; 5 RCTs). From 
this study the authors concluded that GnRH-agonists should not be used for final 
oocyte maturation when fresh embryo transfer was taking place. The authors did 
however recommend the use of GnRH-agonists in the population that posed a 
very high risk of developing moderate to severe OHSS but advised to warn the 
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patients of the potential risk of cycle failure.34 A small prospective, observational 
study looked at a “freeze all” policy when GnRH-agonists were used for final 
oocyte maturation in patients at high risk for OHSS. This study found a cumulative 
on-going pregnancy rate of 36.8% and an on-going pregnancy rate per first frozen-
thawed embryo transfer to be 31.6%.35 
Because of the above studies, the worldwide consensus has been that when a 
GnRH-agonist is used to trigger final oocyte maturation, the resultant embryos are 
then frozen on D3 or D5 and then thawed and transferred in a non-medicated 
natural cycle one month or some months later as opposed to the medicated cycle 
during which the oocytes are extracted.31 The pregnancy rates following frozen-
thawed embryos have always been lower than fresh embryo transfer.36 Frozen-
thawed embryo transfer has been found to have a cost benefit as one can retrieve 
numerous oocytes per cycle, fertilise them, and then after transferring one or two 
of the resultant embryos the remainder can be frozen and subsequent IVF cycles 
can be shorter and cheaper. However, the place for frozen-thawed embryo 
transfer should be reserved for cases of cost saving and should not ideally be 
used as a first line method in ART.36 
Certain methods have been described in an attempt to improve pregnancy 
outcomes when a GnRH-agonist is used to trigger final oocyte maturation. One 
such method is the freeze all method described by Devroey et al. and supported 
by Griesinger et al.37, 38 in the “freeze all” method, oocytes are collected and 
fertilised and all embryos are frozen and transferred in a non-medicated cycle. 
Other suggestions to improve the pregnancy rate post- induction of ovulation with 
a GnRH-agonist, include the use of a dual trigger of both GnRH-agonist and low 
dose hCG with intensive luteal phase support or intensive luteal phase support 
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alone.39, 40 The optimal luteal phase support is still undecided amongst clinicians, 
with protocols differing from clinic to clinic. A 2011 Cochrane review attempted to 
define the optimum luteal phase support by reviewing randomised controlled trials 
of luteal phase support in assisted reproductive techniques. This review 
investigated the use of progesterone, hCG or GnRH-agonist supplementation in in 
vitro fertilisation or intracytoplasmic sperm injection cycles. It also analysed 
different combinations of progesterone and oestrogen, different preparations and 
routes of administration of progesterone as well as combinations of progesterone 
with either hCG or GnRH-agonists. The authors concluded that progesterone 
seemed to be the best option for luteal phase support, with synthetic progesterone 
showing better results than micronized progesterone. The review showed benefit 
to adding a GnRH-agonist to progesterone when looking at live birth, clinical 
pregnancy and on-going pregnancy. Of particular interest to the reviewers was the 
significant increase in OHSS when hCG was used either alone or in combination 
with progesterone and the reviewers recommended avoiding hCG entirely. As 
much as this review seems to favour progesterone alone, the reviewers did 
caution against the results as the number of studies in each comparison was small 
and there was a high risk of type 2 error in most included studies.41 
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3.  Problem statement 
The risk of developing OHSS post-induction of ovulation in patients undergoing 
IVF has been greatly reduced by the introduction of GnRH-agonists for ovulation 
induction. The pregnancy outcomes have not been fully evaluated and specifically 
not when fresh embryo transfer takes place on day three or day five of the 
medicated cycle as opposed to frozen embryo transfer in a fresh non-medicated 
cycle. Vitalab Centre for Assisted Conception performs IVF cycles using a GnRH-
agonist to trigger final oocyte maturation and transfers the resultant embryos in the 
same medicated cycle from which the oocytes were extracted. As this is an 
unconventional method the researcher felt it necessary to study the patients that 
have undergone GnRH-agonist-trigger IVF and to determine the pregnancy 
outcomes and incidence of OHSS.  
The aim of this study was to evaluate the pregnancy rates achieved in GnRH-
agonist ovulation induction IVF cycles and to evaluate the rate of moderate to 
severe OHSS in this group. Our aim was to show that there was no improvement 
in pregnancy outcomes when embryos are frozen and transferred in a non-
medicated cycle as is the current practice while practically eliminating the risk of 
OHSS. 
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4. Objectives 
1..To evaluate the incidence of moderate to severe OHSS in patients undergoing 
GnRH-agonist induced ovulation (Mild OHSS is seen in almost all cases of ovarian 
stimulation for IVF and thus only cases of moderate, severe or critical will be 
assessed) 
2..To evaluate the pregnancy rates achieved when GnRH-agonist-induced 
ovulation takes place and embryos are not frozen  
3..To assess parameters such as stimulation drug used, pre-trigger oestrogen 
values and pre-treatment AMH and evaluate them with regards to pregnancy 
outcomes in order to isolate the best candidates for GnRH-agonist induced 
ovulation induction. 
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5. Methods 
5.1 Setting 
The Vitalab Centre for Assisted Conception was the setting for this study. Vitalab 
is a leading fertility clinic in South Africa. Drs' Jacobson, Gobetz and Volschenk 
are registered Reproductive Medicine Specialists with the Health Professions 
Council of South Africa and have a combined experience in excess of 50 years  in 
evaluating and treating infertile couples.  
5.2 Study design 
This was a descriptive study retrospectively analysing the pregnancy outcomes of 
a defined group of patients undergoing final oocyte maturation and ovulation 
induction with a GnRH-agonist. 
5.3 Study Population 
The records of all patients undergoing IVF and placed on the Cetrotide® - 
[cetrorelix acetate (GnRH antagonist)] protocol that underwent ovulation induction 
with Lucrin® - [Leuprorelin acetate (GnRH-agonist)] between the months of April 
2010 to December 2011 were included in the study.     
5.3.1 Inclusion criteria  
The records of patients between the ages of 18 and 35 years old undergoing IVF 
on the Cetrotride® protocol between April 2010 and December 2011 were 
considered for the study.  
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5.3.2 Exclusion Criteria 
Patients found to have poor ovarian reserve were excluded. Poor ovarian reserve 
was based on serum FSH being greater than 10U/L on day three, age greater than 
35 years old and low anti-mullerian hormone (AMH) of less than 1.1ng/ml.42,43 
The reason that poor responders were excluded from the study was that these 
patients are not expected to develop OHSS. When a patient is assessed to be at 
risk of being a poor responder, the patient will automatically be put onto a long 
stimulation protocol with Lucrin downregulation and will therefore not be a 
candidate for Lucrin trigger.  
 
5.3.3 Protocol: 
The following is a summary of the protocol used by Vitalab when GnRH-antagonist 
stimulation is used. 
On day three of the cycle the patient presents to the clinic for a baseline scan and 
a blood test to determine the serum estradiol (E2) and progesterone levels. At this 
point both the male and female start taking antibiotics and antifungals. The current 
protocol uses Ciproflaxacin 500mg twice daily for five days and Fluconazole 
150mg once off as antibiotic and antifungal therapy as per the Vitalab protocol 
based on international data. Recent studies have shown an improvement in 
pregnancy outcome in patients with repeated IVF failure after the use of the 
antibiotics and antifungals mentioned. One hypothesis is that the reason for 
pregnancy failure could be a benign intrauterine infection.44 The day of the scan 
becomes known as D1 of the stimulation. On day 1 of the stimulation either Gonal-
f® [(follitropin alfa made by Merck)] or Menopur® [(menotropins made by Ferring)] 
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is started. These drugs are both forms of exogenous FSH. The dosage and drug 
used depends on the patient’s prior response, antral follicle count, age, AMH and 
body mass index (BMI) and is calculated based on the current recommended 
protocols as stipulated in the Journal of Fertility and Sterility. This is continued until 
day 6 of the stimulation when a ultrasound scan is done and an E2 level is 
checked. Based on the scan and E2 level Cetrotide® – GnRH antagonist is started 
on either D6 or D7 and its role is to suppress the natural LH surge. At this point 
both Cetrotide® and either Gonal-f® or Menopur® is being administered daily. The 
patient will then be scanned either daily or every second to third day depending on 
the scan findings and E2 levels until there are at least 2 leading follicles of 17mm 
or greater in size each. It is at this point when the drug of choice to trigger final 
oocyte maturation and ovulation will be decided upon. This decision is based on 
the number of follicles and the E2 levels at the time of the trigger. If the patient has 
more than 18 leading follicles or the estradiol levels are greater than 18000pmol/L 
(±4900pg/ml) the patient will undergo a GnRH-agonist trigger for final oocyte 
maturation and ovulation. Patients not showing signs of being at high risk of 
developing OHSS either based on the number of follicles or the E2 levels will then 
be given Ovidrel as the ovulation induction agent. E2 and progesterone levels are 
checked pre-trigger and post trigger. Roughly 36 hours post trigger transvaginal 
oocyte collection takes place in theatre under conscious sedation. 
 
Embryo transfer and luteal phase support post GnRH-agonist trigger  
Patients that have undergone GnRH-agonist trigger receive Gestone® 
(intramuscular progesterone preparation) 100mg injection intramuscular daily 
along with Estro-Pause® (oral estradiol valerate) 2mg tablets twice daily and 
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Estraderm TTS patch® (transdermal estradiol system) replaced every second day. 
These patients are also on Folic Acid 5mg daily from before the cycle and start 
Ecotrin® (enteric coated acetylsalicylic acid) 81mg daily on the day of embryo 
transfer. These patients will also have a quantitative βhCG on D14 if the embryo/s 
had been transferred on D3 or D12 if the embryo/s had been transferred on D5.  
Clinical pregnancy is defined as a positive fetal heart on transvaginal ultrasound at 
7 weeks post embryo transfer.  A biochemical pregnancy is defined as a positive 
serum βhCG on day 14 or day 12 post embryo transfer depending on which day 
embryo transfer took place. 
5.4 Sampling and Sample size 
All relevant files during the predefined study period were retrieved and evaluated. 
A total number of 59 files were reviewed and included in the study. 
All patients undergoing ART on the Cetrotide protocol except those fulfilling the 
exclusion criteria were included in the study.  
5.5 Data collection 
The data were collected by the researcher. All cases of assisted reproduction have 
been recorded in a register at the Vitalab Centre for Assisted Conception. With the 
assistance of the filing clerk, all patients that underwent IVF on the Cetrotide® 
(GnRH antagonist) protocol during the predetermined study period were isolated 
and their files drawn. Patients were then selected according to the inclusion and 
exclusion criteria set out in the study protocol. Those cases eligible for the study 
were assigned a patient number which can only be traced back to the file by the 
researcher thereby ensuring anonymity of the patients. All relevant data were 
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recorded on a data sheet, an example of which is attached. The data were then 
translated into an Excel spread sheet for analysis.  
5.6 Data analysis 
Once all the data had been collected and transferred onto a spread sheet, the data 
were analysed with the assistance of a statistician. Descriptive data were 
described using means with standard deviations and modes with ranges. 
Analytical statistics comprised of Student’s T test for comparisons of means and 
the Chi-squared test for comparisons of frequencies.  
5.7 Ethics 
Total anonymity of the patients included in the study was maintained throughout. 
Ethical clearance was obtained from the Human Research Ethics Committee 
(Medical) of the University of the Witwatersrand. (Appendix) 
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6.  Results 
6.1 Demographics and pregnancy history 
During the collection period a total of 59 patients satisfied the inclusion criteria 
described above. Of the 59 cases reviewed, the age of the patients ranged 
between 20 and 35 with the mean age being 30.55 (SD 3.3).  
Table 1: Range of age of patients in the study 
Age Frequency Percentage (%) 
20-25 4 7 
26-30 23 39 
31-35 32 54 
 
Fifty one out of the 59 patients had never had a viable pregnancy resulting in a 
primary infertility rate of 86%. Of the 8 patients that had live births previously, 6 
had had one child and 2 had two children. 
Table 2: Gravidity of the patients included in the study 
Gravidity Frequency Percentage % 
0 35 59 
1 17 29 
2 2 3 
3 3 5 
4 2 3 
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Seventeen of the patients had experienced at least one miscarriage. Two of the 
patients had sustained ectopic pregnancies previously. 
Table 3: Incidence of miscarriage amongst the patients on the study 
Miscarriages Frequency Percentage % 
0 42 71 
1 11 19 
2 4 7 
3 1 2 
4 1 2 
 
6.2 Pre-treatment work up 
A pre-treatment antral-follicle count was performed on all patients. Patients with 
more than 12 antral follicles were said to have “polycystic-like ovaries”. 
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Table 4: Ranges of antral follicle counts in the right ovary of all patients 
included in the study 
Antral follicle count – 
right (n) 
Frequency Percentage % 
0-3 7 12 
4-6 15 25 
7-9 9 15 
10-12 5 8 
>12 23 39 
 
Table 5: Ranges of antral follicle counts in the left ovary of all patients 
included in the study 
Antral follicle count – left 
(n) 
Frequency Percentage % 
0-3 9 15 
4-6 11 19 
7-9 7 12 
10-12 7 12 
>12 25 42 
 
The antral follicle counts were recorded for right and left ovary as opposed to a 
total number as this is the convention in which the antral follicles are counted at 
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the clinic where the study was conducted. This is because some patients may 
have a poor antral follicle counts on one side and when stimulated one does not 
become alarmed when a good response is seen on only one of the sides. One of 
the patients did not have a left ovary due to previous pelvic surgery. The patient 
with only one ovary had an antral follicle count of 5 in the right ovary.  
The pre-treatment AMH levels ranged from 1.6ng/ml to 48.5ng/ml with an 
interquartile range (IQR) of 2.9ng/ml to 8.7ng/ml and a median of 5.4ng/ml. 
Pre-treatment FSH had in IQR of 5.5U/L to 7.8U/L and a median of 6.4U/L.  
6.3 Cycle specific data 
The mean D2 E2 level was 124pmol/L with an IQR of 71pmol/L to 183pmol/L and 
the mean D2 progesterone level was 1.4pmol/L.  
The most commonly used drug for stimulation was Menopur® with second most 
popular choice being a combination of Menopur® and Gonal-F®.  Fifteen percent 
of the patients were stimulated with Gonal-F® alone.   
 
Table 6: Stimulation drug used   
Drug Number of patients (n) Percentage % 
Menopur® 31 53 
Gonal-F® 9 15 
Combination of above 
drugs 
19 32 
The average stimulation duration was 9.1 days (SD±1.5) The shortest stimulation 
took 4 days and the longest a total of 14 days.   
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Forty eight (81%) of the 59 patients had more than 18 leading follicles at 
stimulation. The average leading follicle size was 16.8mm with a standard 
deviation of 1.4.   
Table 7: Size of leading follicles  
Size of Leading 
Follicles (mm) 
Frequency Percentage % 
13 1 1.7 
14 1 1.7 
15 8 30.6 
16 17 29 
17 13 22 
18 13 22 
19 5 18.5 
20 1 1.7 
 
The IQR for the pre-trigger E2 levels ranged between 12 575pmol/L and              
23 672pmol/L, with a median of 19 552pmol/L.  The lowest pre-trigger E2 was 
740pmol/L and the highest was 43 493pmol/L.   
Seven (12%) of the 59 subjects were coasted. Only one patient developed 
moderate ovarian hyper stimulation syndrome.   
The mean number of oocytes collected was 12.5 with two patients having no 
oocytes collected, and the greatest number of oocytes collected totalling 28.   
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Table 8: Number of Oocytes Collected 
Number of Oocytes 
Collected 
Frequency Percentage % 
0-5 5 8 
6-10 12 20 
11-15 28 48 
16-20 11 19 
>20 3 5 
 
6.4 Choice of artificial reproduction technique 
Thirteen of the 59 patients underwent ICSI alone. Thirty seven of the 59 patients 
underwent IVF.  Six of the patients had both ICSI and IVF performed, a further 2 
patients had zygote intra-fallopian tube (ZIFT) and 1 patient had gamete intra-
fallopian tube (GIFT).   
6.5 Fertilisation results 
Fertilisation was deemed successful when two pronuclei were observed. Four of 
the patients did not have oocytes fertilised.  One of the patients had 20 oocytes 
fertilised. The most frequent number of oocytes fertilised was 9.   
6.6 Embryo transfer 
Four patients did not have embryo transfer performed while 25 of the 59 had 
embryo transfer on day 5. Twenty-seven of the 59 had embryo transfer on day 3.  
Of the 4 patients that had no embryo transfer; 1 had 8 oocytes collected, all of 
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which were used for IVF, seven were fertilized but none were of adequate quality 
for a transfer. Two of the patients had no embryo transfer as no oocytes were 
collected, the remaining 1 patient had 19 oocytes collected, 14 were used for ICSI, 
but none fertilised.  The patient that underwent GIFT had embryo transfer on D5.   
6.7 Frozen embryos post embryo transfer 
Forty of the 59 patients either chose not to freeze any embryos or did not have 
embryos of adequate quality for freezing post embryo transfer.   
5.8 Pregnancy outcomes and rates 
The biochemical pregnancy rate was 39% at day 14 post embryo transfer 
indicated by a serum βhCG of greater than 10IU/L.  Twenty of the 59 patients had 
a clinical pregnancy at the seven week ultrasound yielding a clinical pregnancy 
rate of 34%. A clinical pregnancy was deemed such by the presence of at least 
one fetal heart at the seven week ultrasound. The singleton rate was 22%, 6.8% of 
the patients had at least two fetal hearts at the seven week ultrasound and 3.4% of 
the patients had three foetal hearts at 7 week ultrasound.    
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7.  Discussion 
7.1 Demographics and Pregnancy History 
The mean age of patients in our study was 30.5 years. This classifies the majority 
of our patients into a young group for assisted reproduction and hence a group at 
high risk for developing OHSS. Comparing our mean age to that in other similar 
studies, the mean age in the study by Imbar et al was 30.0 years in the fresh 
embryo transfer group which is exactly what we found.40 The mean age in the 
study by Manzanares et al was 33.9 years for the GnRH-agonist induction cycle 
which puts our patients at higher risk for developing OHSS.31    
Fifty one out of 59 patients had primary infertility, showing that a high percentage 
of patients had not successfully carried a pregnancy to viability before. 
7.2 Pre-Treatment Work Up 
As this study was aimed at those patients at high risk for OHSS it was interesting 
to note that of the patients included in the study, 39% had polycystic-like ovaries in 
the left ovary, while 43% showed polycystic-like ovaries in the right ovary. Since 
our study was aimed at finding the best possible trigger for final oocyte maturation 
in the patient with a high risk of developing OHSS, the above finding showed that 
the patients included in this study did fulfil the criteria for the at-risk patient.  
The AMH levels had a wide range with those patients with the highest antral 
follicle count also having the highest AMH.  Women with an AMH <1.1ng/ml were 
excluded from the study.  The lowest AMH included was 1.6ng/ml which was 
above the 1.1ng/ml limit chosen. The high level of AMH amongst the study 
population was also indicative that these patients were at high risk for developing 
OHSS.    
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7.3 Cycle-Specific Data 
Of interest was the clinicians’ preference to use Menopur® as the drug of choice 
for controlled ovarian stimulation.  The biochemical pregnancy rate with Menopur® 
when used for stimulation was 38% as opposed to the biochemical pregnancy rate 
of 20% when Gonal-F® was used.  When a combination of Gonal-F® and 
Menopur® were used, the biochemical pregnancy rate was 37%. The choice of 
which drug to use for stimulation was based purely on the clinician’s opinion and 
the response of the patients involved. If a patient’s response was poor then the 
drug was changed. Some patients were known to have had poor response from 
one of the drugs and were then stimulated with the other. There was no formula or 
specific protocol in place for choice of drug for stimulation and perhaps a 
randomised control trial may be needed to fully evaluate the best option for 
ovarian stimulation.     
7.4 Appropriate use of GnRH-agonist Trigger  
In the study by Aljawoan et al, quoted in the literature review, patients with more 
than 20 follicles at the time of ovulation induction were examined. Among this 
group of patients, 10.4% of those that had three leading follicles greater than 
15mm and a serum estradiol level greater than 1635pg/ml (±6000pmol/L) 
developed moderate to severe OHSS16.  In a review by Humaidan and Kol 
published in the Reproductive Biomedicine Online as recently as 2013, the most 
important primary risk factors for OHSS were a high AMH, high antral follicle 
count, PCOS or isolated PCOS characteristics and a previous history of OHSS. 
Their recommendation for when to trigger with a GnRH-agonist was when there 
are more than 14 follicles greater than 11mm on the day of trigger.45 The results of 
our study showed that 48 out of 59 patients had more than 18 leading follicles with 
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the mean leading follicle size being 16.8mm.  This puts the majority of patients in 
the study at high risk for developing OHSS, however only 1 patient developed 
moderate OHSS.  The pre- trigger E2l levels with a median of 19 552pmol/L also 
indicate that these patients were at great risk for OHSS. Papanikolaou et al in 
Fertility and Sterility showed that a threshold of 18 or more leading follicles and or 
a pre-trigger estradiol level of greater than ±6000pmol/L yielded an 83% sensitivity 
and 84% specificity for severe cases of OHSS.25   
Interestingly only seven patients in our study required coasting which implies that 
they were not hyper-stimulated.  
7.5 Cycle Outcomes 
Only 2 patients did not have oocytes collected and three patients had more than 
20 oocytes with a mean number of 12 oocytes collected- this shows a COH with 
good outcomes with regard to oocytes collected. IVF was by far the most popular 
method of assisted reproduction.  The fertilization rates of 93% showed good 
oocyte quality.  Day 3 was the most popular day for embryo transfer.  No patients 
underwent frozen embryo transfer on this study.   
7.6 Pregnancy Outcomes 
In the study by Manzanares et al, embryo transfer was conducted using only 
frozen embryos.  The pregnancy rate quoted in this study is 33%.31    
In the meta-analysis by Griesinger, clinical pregnancy rates were significantly 
reduced using a GnRH-agonist for ovulation induction with an odds ratio of 0.22, 
(95% CI = 0.05-0.85, p=0.03), and the study concluded that GnRH-agonist 
triggering significantly reduced the clinical pregnancy when fresh embryos were 
transferred in the treatment cycle.33 
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The Cochrane review by Youssef et al showed similar results to the meta-analysis 
by Griesinger et al and also recommended that GnRH-agonists should not be 
used for final oocyte maturation when fresh embryo transfer was taking place.34   
In the prospective observational study by Griesinger et al quoted in the literature 
review, the on-going pregnancy rates in a “freeze all policy” when using a GnRH-
agonist for final oocyte maturation was found to be 31.6%.38  
Imbar et al however, showed in a 2012 study that the clinical pregnancy rate of 
fresh embryo transfer was 37% when the GnRH-agonist was used for final oocyte 
maturation.40  In that study an intensive luteal phase support including 50mg of 
intra-muscular progesterone and 6mg of 17-β-estradiol was utilised similar to the 
luteal phase support used in our study. The pregnancy rates in our study were 
similar to those described in the study by Imbar et al and greater than the 
pregnancy outcomes in the meta-analysis by Griesinger quoted above.34   
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8.  Limitations 
One of the limitations of this study was that live birth rate was not represented.  
According to an opinion published in the Journal of Reproductive Genetics, live 
birth rate is the gold standard for the measurement of success in assisted 
reproduction.46  The reason for not including live birth rate in this study is that 
patients were only followed up for a maximum of 10 weeks gestation. The Vitalab 
Centre for Assisted Conception does not have an obstetrics unit and once patients 
have been scanned at seven and ten weeks and are found to have normal on-
going pregnancies they are then referred to either an obstetrician recommended 
by the clinic or to an obstetrician of the patient’s choice. All patients under-going 
treatment at the Vitalab Centre for Assisted Conception have given consent for 
their records to be used for medical research, however these patients have not 
given permission to be contacted to find out about the outcome of the pregnancy. 
Although many of the patients or obstetricians that the patients consult will inform 
the clinic of the outcome of the pregnancy, this information was not available in the 
patient’s file. For this reason live birth was not used as a variable in the success of 
the assisted reproduction although the researcher feels this would have added 
weight to the study. 
A further limitation is that only one institution was used to collect data. If more than 
one clinic was used it would have added to the total number of patients, possibly 
excluded any bias with regard to patient selection and physicians possible 
preference for choice of drugs. As the luteal phase support protocol at the Vitalab 
Centre for Assisted Conception is also uniform across all the attending physicians, 
the possibility of the luteal phase support being the crucial factor in the success of 
the reproductive cycles was also not fully evaluated. Had the research taken place 
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at other centres, the luteal phase support would most likely have had some variety 
and this would have assisted the researcher in deciding how much of an impact 
the luteal phase support has had on the pregnancy outcomes. 
A further limitation to this study is that the data collected were compared to similar 
studies in the literature but not compared to patients at our centre that were 
triggered with hCG.  However as set out in the objectives of this study, the aim of 
this study was to assess pregnancy outcomes in a group of patients that were high 
risk of developing OHSS and hence were triggered with Lucrin. We also set out to 
show that transferring fresh embryos in a cycle where Lucrin was used as a trigger 
for ovulation as opposed to freezing the embyos does not impact on the 
pregnancy rates as compared with data published internationally.  
The author does however acknowledge that a more suitable and scientifically 
sound approach would have been to perform a prospective study by randomising 
patients triggered with Lucrin into fresh embyo transfer group and a group that 
underwent frozen embryo transfer in a natural cycle.  
Lastly, the stimulation protocols used in this study were not fixed for each patient 
but rather decided on by the clinician, which meant that the stimulation drugs used 
were not uniform throughout the study.   
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9.  Conclusion 
The mean age of 30.5 years, high antral follicle counts, high AMH levels, a large 
number of patients with more than 18 leading follicles with a mean size of 16.8mm 
at the time of the trigger and the high mean estradiol levels pre-trigger make this 
group high risk for developing OHSS. 
Our study shows that the use of GnRH-agonists to trigger final oocyte maturation 
in assisted reproduction is associated with a low incidence of OHSS in high risk 
patients. Our findings are similar to other published data and support other such 
studies. 
This study, to the best of the researcher’s knowledge, is the first of its kind to be 
done in South Africa.  We have shown the biochemical and clinical pregnancy 
rates to be acceptable when GnRH-agonists are used for final oocyte maturation 
and embryos are transferred fresh in the medicated cycle.  This evidence suggests 
that embryos should not be frozen as this worsens the stress and time constraints 
of a couple undergoing assisted reproduction without an improvement in the 
outcomes.   
The  difference in pregnancy outcomes in patient stimulated with Menopur® 
versus Gonal-F® needs further work and may just be coincidental.  
The intensive luteal phase support used by Vitalab Centre for Assisted 
Conception, may explain the excellent biochemical and clinical pregnancy rates.  
Further work needs to be done to ascertain whether the pregnancy rates would be 
as good with the use of less intense luteal phase support therapy.   
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APPENDIX A:  DATA SHEET 
Past History 
Patient # - ____________________________Age - _____________________________ 
Parity - ____________________________Gravidity - _________________________ 
Miscarriages - ______________________Ectopics - __________________________ 
Pre – treatment AFC (Antral follicle count) -RIGHT _______ LEFT__________ 
Pre – treatment AMH (Anti-Mullerian hormone) - _________________ 
Pre-treatment FSH (Follicle stimulating hormone)_________________ 
Cycle data 
Day 2 Estrogen  
Day 2 Progesterone  
Stimulation drug used  
Stimulation duration  
Stimulation dose used  
Number of leading follicles <18                            >18 
Size of leading follicles  
Estrogen value pre-trigger  
Progesterone pre-trigger  
Trigger drug  
Trigger dose  
Number of ocytes collected  
# of oocytes for IVF  
# of oocytes for ICSI   
# of oocytes for ZIFT  
# of oocytes for GIFT  
Total fertilised  
Day transferred  
# of frozen embryos  
Β-hCG – 1  
Β-hCG – 2  
Β-hCG – 3  
Sonar - # of gestational sac  
Sonar - # of fetal hearts  
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APPENDIX B: Consent form signed by patients  
 
 
 
CONSENT FORM FOR PARTICIPATION IN THE  
ASSISTED REPRODUCTION PROGRAMME INCLUDING : 
 
 
A) IN-VITRO FERTILISATION AND EMBRYO TRANSFER  -  IVF 
 
B)       INTRACYTOPLASMIC SPERM INJECTION  -  ICSI 
 
C)       GAMETE INTRA-FALLOPIAN TRANSFER  -  GIFT 
 
D) OTHER ASSISTED REPRODUCTIVE TECHNOLOGIES 
 
 
1) We hereby authorise and direct the Gynaecologist(s), Drs Jacobson, Gobetz and Volschenk 
and such assistants as may be selected by them to administer and to treat 
 
__________________________________________________________________   
                                         FULL NAMES OF COUPLE 
 
In accordance with the protocols which we have read and which have been discussed with 
us, and we hereby consent to such treatment. 
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2) We understand that it may be necessary to produce a semen (sperm) sample to be frozen.  
This will be used for back-up purposes and will be thawed on the day of oocyte retrieval.  If 
it is not required, it will be discarded after the procedure. 
 
3) We understand that medical aid coverage for any or all of the above procedures may not 
be available and that we are personally responsible for the expenses incurred during 
treatment.  These expenses have been discussed with me by the medical team. 
 
4) We understand that we are free to discontinue participation in the treatment programme 
at any time, either verbally or in writing.  We also understand that, if we do decide to 
discontinue participation in the programme, we will be responsible for all expenses 
incurred during the period prior to discontinuation and which relate to such treatment. 
 
5) We understand that this consent extends from the original period in the treatment 
programme until the treatment is completed or until we decide to discontinue 
participation.  Further, this consent is binding for participation in subsequent treatment 
programme. 
 
6) We understand that, should the results of my treatment or any aspect of it be published 
in medical or scientific journals, all possible precautions will be taken to protect my 
anonymity.  We grant permission to the medical team to publish in professional journals 
relating to our case, provided our names are not used. 
 
7) We have read and understand this consent form and all our questions have been answered 
to our satisfaction.  All blanks were filled prior to signature. 
 
 
 
DATE:  ……………………………………………………………………………...  
 
     
SIGNATURE OF WOMAN: ……………………………………………………………… 
 
 
SIGNATURE OF MAN: ………………………………………………………………  
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SIGNATURE OF DOCTOR: ……………………………………………………………… 
 
 
SIGNATURE OF PERSON OBTAINING CONSENT: ………………………………. 
 
 
WITNESS:  ………………………………………………………………………. 
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APPENDIX C: ETHICS CLEARANCE 
 
 
